Novo Nordisk - Enough Is Enough: 5 Reasons It's Time To Sell (Rating Downgrade)

Sell on Novo Nordisk A/S: slowing growth, downgraded 2025 guidance, rising GLP-1 competition, pricing/patent risks, limited ...

Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation

Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.

Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials

Rich Pelt, senior director of Global Regulatory Sciences at Pfizer gives tips for navigating the rapidly changing regulatory ...

C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab

C4 Therapeutics (NASDAQ:CCCC) outlined near-term clinical plans for its targeted protein degradation pipeline during a presentation at Barclays’ 28th Annual Global Healthcare Conference, highlighting ...
The Sun Chronicle

White House war promo videos marry action movies, sports and video games to real-life combat footage

Peaceful and violent, in video game screenshots and movie clips and on professional playing fields, the icons come fast and ...
Barron's

Pfizer Inc.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide.